Yûichi Murakami
YOU?
Author Swipe
View article: Microcurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer
Microcurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer Open
5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for breast cancer. Its efficacy relies on the function of p53, and mutations in p53 contribute to the development of resistance during 5-FU chemotherapy. Here, we report that …
View article: Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer
Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer Open
Y-box binding protein 1 (YBX1) promotes oncogenic transformation and tumor growth. YBX1 plays a role in regulation of cell cycle promotion via upregulation of cell cycle-related genes. In ovarian cancer, YBX1 also promotes tumor growth, bu…
View article: Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes
Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes Open
5-azacytidine (AZA), a representative DNA-demethylating drug, has been widely used to treat myelodysplastic syndromes (MDS). However, it remains unclear whether AZA’s DNA demethylation of any specific gene is correlated with clinical respo…
View article: Strain-induced specific orbital control in a Heusler alloy-based interfacial multiferroics
Strain-induced specific orbital control in a Heusler alloy-based interfacial multiferroics Open
For the development of spintronic devices, the control of magnetization by a low electric field is necessary. The microscopic origin of manipulating spins relies on the control of orbital magnetic moments ( m orb ) by strain; this is essen…
View article: Dielectric‐Breakdown Properties of Ester Oil Prepared from Thermally Degraded Rice Oil
Dielectric‐Breakdown Properties of Ester Oil Prepared from Thermally Degraded Rice Oil Open
The vegetable‐insulating oils are used in electrical systems recently. Most of vegetable‐insulating oils are manufactured from new oils. In this paper, we propose to develop the insulating oils from the used cooking oil. The used cooking o…
View article: Elevated expression of N-myc downstream regulated gene 1 protein promotes neovascularization and tumor progression in glioblastomas
Elevated expression of N-myc downstream regulated gene 1 protein promotes neovascularization and tumor progression in glioblastomas Open
Aim The N-myc downstream regulated gene 1 ( NDRG1 ) is a member of the NDRG family, of which four members ( NDRG1, NDRG2, NDRG3, NDRG4 ) have been identified. NDRG1 is repressed by c-MYC and N-MYC proto-oncogenes. NDRG1 is translated into …
View article: Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.
View article: Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.
View article: Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated by YBX1 phosphorylation at serine 102 by AKT, p70S6K, a…
View article: Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.
View article: Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
YBX1 and pYBX1 (S102) expression of 397 invasive breast cancer patients obtained from TCGA (Breast Invasive Carcinoma (TCGA, Provisional).
View article: Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.
View article: Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.
View article: Data from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
Data from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells Open
Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-bi…
View article: Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.
View article: Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.
View article: Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Data from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated by YBX1 phosphorylation at serine 102 by AKT, p70S6K, a…
View article: Data from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
Data from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells Open
Gene amplification of HER2/ErbB2 occurs in gastric cancer and the therapeutic efficacy of the HER2-targeted antibody, trastuzumab, has recently been improved against HER2-positive advanced stomach cancer. Here, we examined whether Y-box-bi…
View article: Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Supplementary Materials and Methods
View article: Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S3 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.
View article: Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Figure S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.
View article: Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S2 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
YBX1 and pYBX1 (S102) expression of 397 invasive breast cancer patients obtained from TCGA (Breast Invasive Carcinoma (TCGA, Provisional).
View article: Supplementary Table 1 from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
Supplementary Table 1 from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells Open
PDF File - 66K, Sensitivity to lapatinib, erlotinib, SU11274, cisplatin and CPT-11 in human gastric cancer cell lines.
View article: Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary information from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Supplementary Materials and Methods
View article: Supplementary Table 1 from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
Supplementary Table 1 from Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells Open
PDF File - 66K, Sensitivity to lapatinib, erlotinib, SU11274, cisplatin and CPT-11 in human gastric cancer cell lines.
View article: Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance
Supplementary Table S1 from Targeting Phosphorylation of Y-Box–Binding Protein YBX1 by TAS0612 and Everolimus in Overcoming Antiestrogen Resistance Open
Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.
View article: Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma
Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma Open
ST1:Clinical characteristics of 28 patients with GBM, from whom tumor samples are analyzed.
View article: Data from Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression
Data from Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression Open
Endocrine therapies effectively improve the outcomes of patients with estrogen receptor (ER)-positive breast cancer. However, the emergence of drug-resistant tumors creates a core clinical challenge. In breast cancer cells rendered resista…
View article: Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma
Supplementary Table S1 from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma Open
ST1:Clinical characteristics of 28 patients with GBM, from whom tumor samples are analyzed.
View article: Supplementary Figures from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma
Supplementary Figures from Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma Open
SF1: NDRG1 silencing upregulates GSK3β expression and cell growth signaling pathways; SF2: NDRG1 overexpression suppresses cell growth, GSK3β expression and cell growth signaling pathways; SF3: Effect of WT and Î"6 deletion mutant of NDR…